Medicare Benefits Schedule - Item 73313

Development of a quantitative patient‑specific molecular assay for measurable residual disease (MRD) testing performed on bone marrow (or a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia treated with combination chemotherapy or after salvage therapy, including the first service described in item 73316 performed on that bone marrow or peripheral blood sample, requested by a specialist or consultant physician practising as a haematologist or oncologist

Applicable once per patient per episode of disease or per relapse

Fee: $3,000.00 Benefit: 75% = $2,250.00 85% = $2,901.30

(See para PN.7.20 of explanatory notes to this Category)

• Previous - Item 73312
• Next - Item 73314

The number of measurable residual disease (MRD) tests per patient, per episode of disease or per relapse is not expected to exceed 12, inclusive of a baseline assessment.

Related Items: 73313 73316